Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cirrhosis can occur with the development of portal vein thrombosis (PVT). PVT may aggravate portal hypertension, and it can lead to hepatic decompensation. The international guideline recommends for anticoagulation treatment to be maintained for at least 3 months in all patients with acute PVT. Low-molecular-weight-heparin and changing to warfarin is the usual anticoagulation treatment. However, warfarin therapy is problematic due to a narrow therapeutic window and the requirement for frequent dose adjustment, which has prompted the development of novel oral anticoagulants for overcoming these problems. We report a 63-year-old female who experienced complete resolution of recurrent acute PVT in liver cirrhosis after treatment with rivaroxaban. (Clin Mol Hepatol 2016;22:499-502)
Abstract
Cirrhosis can occur with the development of portal vein thrombosis (PVT). PVT may aggravate portal hypertension, and it can lead to hepatic decompensation. The international guideline recommends for anticoagulation treatment to be maintained for at least 3 months in all patients with acute PVT. Low-molecular-weight-heparin and changing to warfarin is the usual anticoagulation treatment. However, warfarin therapy is problematic due to a narrow therapeutic window and the requirement for frequent dose adjustment, which has prompted the development of novel oral anticoagulants for overcoming these problems. We report a 63-year-old female who experienced complete resolution of recurrent acute PVT in liver cirrhosis after treatment with rivaroxaban. (Clin Mol Hepatol 2016;22:499-502)
참고문헌 (21)
- EINSTEIN Investigators, "Oral rivaroxaban for symptomatic venous thromboembolism", N Engl J Med, 363, pp.2499~2510 (2010)
- Valla DC, "Spectrum of portal vein thrombosis in the West", J Gastroenterol Hepatol, 17(Suppl 3), pp.S224~S227 (2002)
- Sarin SK, "Consensus on extra-hepatic portal vein obstruction", Liver Int, 26, pp.512~519 (2006)
- Okuda K, "Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients", Gastroenterology, 89, pp.279~286 (1985)
- Francoz C, "Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation", Gut, 54, pp.691~697 (2005)
- Amitrano L, "Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis", J Hepatol, 40, pp.736~741 (2004)
- Condat B, "Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study", Hepatology, 37, pp.1302~1308 (2003)
- Sarin S, "Portal biliopathy in extrahepatic portal vein obstruction", Indian J Gastroenterol, 2, pp.A82~ (1992)
- -1,3- oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An Oral, Direct Factor Xa Inhibitor, "J Med Chem", 2005, 5900~5908
- Mann KG, "What is all that thrombin for?", J Thromb Haemost, 1, pp.1504~1514 (2003)
- Perzborn E, "In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor", J Thromb Haemost, 3, pp.514~521 (2005)
- Smythe MA, "Rivaroxaban: practical considerations for ensuring safety and efficacy", Pharmacotherapy, 33, pp.1223~1245 (2013)
- Holbrook AM, "Systematic overview of warfarin and its drug and food interactions", Arch Intern Med, 165, pp.1095~1106 (2005)
- Bates SM, "Clinical practice. Treatment of deep-vein thrombosis", N Engl J Med, 351, pp.268~277 (2004)
- Intagliata NM, "Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation", Dig Dis Sci, 61, pp.1721~1727 (2016)
- Lenz K, "Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban", Z Gastroenterol, 52, pp.1175~1177 (2014)
- Pannach S, "Successful treatment of acute portal vein thrombosis with rivaroxaban", Thromb Haemost, 110, pp.626~627 (2013)
- Martinez M, "Treatment of acute portal vein thrombosis by nontraditional anticoagulation", Hepatology, 60, pp.425~426 (2014)
- Pabinger I, "Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening", Blood Coagul Fibrinolysis, 3, pp.547~553 (1992)
- Hansson PO, "Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors", Arch Intern Med, 160, pp.769~774 (2000)
- Primignani M, "Therapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosis", World J Hepatol, 7, pp.2906~2912 (2015)